Aktuelle Kontroversen in der adjuvanten systemischen Therapie des Mammakarzinoms

Zusammenfassung

Die Sterblichkeit von Brustkrebs konnte, vor allem dank der Früherkennung und systemischer Therapiemaßnahmen, seit den 90er-Jahren signifikant gesenkt werden. Allerdings steht eine Reihe von modernen Therapieformen aufgrund ihrer größeren Nebenwirkungen und der hohen Kosten im Zentrum der Kritik. Häufig stehen die Frauenärztin oder der Frauenarzt vor der Therapieentscheidung zwischen einer vermeintlich modernen, aber kontroversen Behandlungsform, oder einer bewährten, aber vielleicht nicht mehr zeitgemäßen Therapie. Dieser Artikel soll einen kurzen Überblick zu den Kontroversen und zum Stand der Evidenz zum Einsatz der Aromataseinhibitoren, der Taxane, der dosisdichten Chemotherapie und von Trastuzumab in der adjuvanten Therapie des Mammakarzinoms geben.

Abstract

On the basis of screening programs and improvements in systemic treatment, mortality in breast cancer patients has significantly declined over the last two decades. On the other hand, modern systemic treatment is frequently associated with severe toxicity and causes vast expenses. On day to day basis, physicians have to decide between conventional and innovative treatment. This article summarizes the most relevant pros and cons for the implementation of aromatase inhibitors, the taxanes, dose dense chemotherapy and the use of trastuzumab in the adjuvant treatment of breast cancer.

Chemotherapie - endokrine Therapie - Radiotherapie - Prognose - Rezidiv - Mammakarzinom - Kontroversen

chemotherapy - endocrine therapy - radiotherapy - prognosis - recurrence - breast cancer - controversies

Literatur

• 1 Early Breast Cancer Trialists' Collaborative Group . Ovarian ablation for early breast cancer.  Cochrane Database Syst Rev. 2000;  CD000485
• 2 Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
• 3 Alexander F E, Anderson T J, Brown H K, Forrest A P, Hepburn W, Kirkpatrick A E, Muir B B, Prescott R J, Smith A. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening.  Lancet. 1999;  353 1903-1908
• 4 Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial.  BMJ. 1988;  297 943-948
• 5 Barratt A L, Les-Irwig M, Glasziou P P, Salkeld G P, Houssami N. Benefits, harms and costs of screening mammography in women 70 years and over: a systematic review.  Med J Aust. 2002;  176 266-271
• 6 Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.  Lancet. 1896;  74
• 7 Citron M L, Berry D A, Cirrincione C, Hudis C, Winer E P, Gradishar W J, Davidson N E, Martino S, Livingston R, Ingle J N, Perez E A, Carpenter J, Hurd D, Holland J F, Smith B L, Sartor C I, Leung E H, Abrams J, Schilsky R L, Muss H B, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.  J Clin Oncol. 2003;  21 1431-1439
• 8 Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  366 2087-2106
• 9 Early Breast Cancer Trialists' Collaborative Group . Multi-agent chemotherapy for early breast cancer.  Cochrane Database Syst Rev. 2002;  CD000487
• 10 Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y. et al . Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.  N Engl J Med. 1989;  320 822-828
• 11 Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thurlimann B, Senn H J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.  Ann Oncol. 2005;  16 1569-1583
• 12 Gotzsche P C. Update on effects of screening mammography - letter to the editor.  Lancet. 2002;  360 338
• 13 Gotzsche P C, Olsen O. Is screening for breast cancer with mammography justifiable?.  Lancet. 2000;  355 129-134
• 14 Gotzsche P C. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality.  Cancer. 2002;  94 578
• 15 Halsted W S. The results of radical operation for the cure of carcinoma of the breast.  Ann Surg. 1907;  46 1-19
• 16 Hanrahan E O, Valero V, Gonzalez-Angulo A M, Hortobagyi G N. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.  J Clin Oncol. 2006;  24 2113-2122
• 17 Jacobson J A, Danforth D N, Cowan K H, d'Angelo T, Steinberg S M, Pierce L, Lippman M E, Lichter A S, Glatstein E, Okunieff P. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.  N Engl J Med. 1995;  332 907-911
• 18 Kudachadkar R, O'Regan R M. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.  CA Cancer J Clin. 2005;  55 145-163
• 19 Kuhn T, Bembenek A, Buchels H, Decker T, Dunst J, Mullerleile U, Munz D L, Ostertag H, Sautter-Bihl M L, Schirrmeister H, Tulusan A H, Untch M, Winzer K J, Wittekind C. [Sentinel node biopsy in breast carcinoma. Interdisciplinary agreement consensus of the German Society for Serology for quality controlled application in routine clinical testing].  Pathologe. 2004;  25 238-243
• 20 Möbus V, Untch M, Du Bois A, Lueck H-J, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 + LN). First results of an AGO-trial.  Proc ASCO. 2004;  22 513
• 21 Nystrom L, Andersson I, Bjurstam N, Frisell J, Rutqvist L E. Update on effects of screening mammography - authors reply to letters to the editor.  Lancet. 2002;  360 340
• 22 Nystrom L, Rutqvist L E, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J. et al . Breast cancer screening with mammography: overview of Swedish randomised trials.  Lancet. 1993;  341 973-978
• 23 Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist L E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials.  Lancet. 2002;  359 909-919
• 24 Olsen O, Gotzsche P C. Cochrane review on screening for breast cancer with mammography.  Lancet. 2001;  358 1340-1342
• 25 Olsen O, Gotzsche P C. Screening for breast cancer with mammography.  Cochrane Database Syst Rev. 2001;  CD001877
• 26 Peto R. Mortality from breast cancer in UK has decreased suddenly [12].  British Medical Journal. 1998;  317 476-477
• 27 Piccart-Gebhart M J, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios C H, Steger G, Huang C S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter T M, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci M S, Gelber R D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 1659-1672
• 28 Sarrazin D, Le M G, Arriagada R, Contesso G, Fontaine F, Spielmann M, Rochard F, Le-Chevalier T, Lacour J. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer.  Radiother Oncol. 1989;  14 177-184
• 29 van-Dongen J A, Bartelink H, Fentiman I S, Lerut T, Mignolet F, Olthuis G, van-der-Schueren E, Sylvester R, Winter J, van-Zijl K. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.  J Natl Cancer Inst Monogr. 1992;  11 15-18
• 30 Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Orvieto E, De Cicco C, Intra M, Tosi G, Scarpa D. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series.  J Natl Cancer Inst. 1999;  91 368-373
• 31 Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.  N Engl J Med. 2003;  349 546-553
• 32 Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, Del-Vecchio M, Mariani L, Zurrida S, Rilke F. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1973 patients.  Eur J Cancer. 1995;  31A 1574-1579
• 33 Winer E P, Hudis C, Burstein H J, Wolff A C, Pritchard K I, Ingle J N, Chlebowski R T, Gelber R, Edge S B, Gralow J, Cobleigh M A, Mamounas E P, Goldstein L J, Whelan T J, Powles T J, Bryant J, Perkins C, Perotti J, Braun S, Langer A S, Browman G P, Somerfield M R. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004.  J Clin Oncol. 2005;  23(3) 619-629